Why Exact Sciences Rallied Over 50% This Week

Group 1 - Exact Sciences' shares surged 50.7% this week, driven by a strong earnings report and acquisition news [1] - Abbott Laboratories announced a formal agreement to acquire Exact Sciences for $21 billion, equating to $105 per share, which is a 59% premium over the share price before acquisition rumors [2][3] - The acquisition aims to enhance Abbott's cancer diagnostics portfolio, targeting a $45 billion market for colon and multicancer screening, a $5 billion treatment guidance technology market, and a $15 billion molecular residual disease detection market [4] Group 2 - Exact shareholders are experiencing a significant premium from the acquisition price, although it remains approximately 33% lower than the stock's all-time high of nearly $160 per share in 2021 [5] - The deal is projected to close in the second quarter of 2026, with Exact's current share price around $101, indicating limited upside potential for shareholders in the near term [7] - Investors are advised to consider exiting Exact Sciences shares soon, as the stock has appreciated close to the buyout price [9]